TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11336370
Drug: Intra-articular ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular ropivacaine injection (20 ml of ropivacaine 0.5%)
Study: 11336370
Drug: Intra-articular ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular ropivacaine injection
Study: 9138046
Drug: 12-week group
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week group cognitive-behavioral therapy (CBT)
Study: 9138046
Drug: Extended cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended cognitive-behavioral therapy (CBT)
Study: 25987796
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Alequel™, an autologous protein‐containing colon extract, 3 doses per week for 15 weeks (total of 45 doses)
Study: 25987796
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Alequel™, an autologous protein‐containing colon extract
Study: 25411597
Drug: Ipragliflozin 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 12.5 mg
Study: 23163880
Drug: Ipragliflozin 150
Normalized name: canagliflozin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 150 mg
Study: 10875716
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron and 1.25 mg droperidol combination
Study: 1355599
Drug: Neostigmine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (administered after vecuronium or atracurium)
Study: 6339331
Drug: Doxycycline (single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (single-dose prophylactic antibiotic)
Study: 30597114
Drug: Self-medication with
Normalized name: chloroxylenol Medicated Pad [E-Z Scrub with Ultradex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication with antimicrobials
Study: 30597114
Drug: Self-medication with
Normalized name: chloroxylenol Medicated Pad [E-Z Scrub with Ultradex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication with antihypertensives or antihyperglycemics
Study: 30597114
Drug: Self-treatment with
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment with antimicrobials
Study: 19013761
Drug: Drug therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapies in RCTs
Study: 12213870
Drug: Lanreotide (LAN)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanreotide (LAN) 60 mg/month (n = 11)
Study: 10233220
Drug: Urea-containing moisturizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea-containing moisturizer applied twice daily for 20 days
Study: 2379229
Drug: Clindamycin 150
Normalized name: clindamycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 150 mg orally four times daily for seven days
Study: 2379229
Drug: Ampicillin 250
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 250 mg orally four times daily for seven days
Study: 78297
Drug: Salbutamol inhalers
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol inhalers used 30 min before inhalation of 100 microgram of beclomethasone dipropionate (B.D.P.)
Study: 25399552
Drug: Dacarbazine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (1000 mg/m² every 3 weeks)
Study: 16954710
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% lidocaine gel
Study: 16954710
Drug: Artificial tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tear gel
Study: 29442086
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ibuprofen orally 1 h before the endodontic procedure (Group A)
Study: 29442086
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibuprofen and low-level laser therapy (Group C)
Study: 29442086
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative ibuprofen nor low-level laser irradiation (Group D)
Study: 24012063
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral and enema mesalazine (4 g/day oral + 1 g enema)
Study: 24012063
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral and enema mesalazine
Study: 24012063
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine (4 g/day)
Study: 22311905
Drug: Immediate-release aspirin
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release aspirin
Study: 18715213
Drug: Insulin guidance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin guidance software (ACCU‐CHEK Advisor)
Study: 15761191
Drug: Torcetrapib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib (120 mg QD)
Study: 15761191
Drug: Torcetrapib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torcetrapib (120 mg BID)
Study: 12454555
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (75 to 225 mg/day)
Study: 12454555
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (37.5 mg, 75 mg, or 150 mg, fixed-dose)
Study: 1673944
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 10 mg BID
Study: 1673944
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (medroxyprogesterone acetate and conjugated estrogens)
Study: 6108592
Drug: Nabilone (comparatively
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (comparatively lower doses)
Study: 28911510
Drug: Lower epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower epinephrine dosage
Study: 19584831
Drug: PEG‐IFN alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alpha‐2b and lamivudine (100 mg/day)
Study: 17426158
Drug: Sulfadoxine-pyrimethamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (25 mg/kg of the sulfadoxine component)
Study: 14692469
Drug: zaleplon 10
Normalized name: zaleplon 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: zaleplon 10 mg
Study: 14692469
Drug: temazepam 15
Normalized name: temazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: temazepam 15 mg
Study: 15198277
Drug: time‐released melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: time‐released melatonin 6 mg
Study: 11351356
Drug: Pycnogenol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (50 mg x 3/day for 2 months)
Study: 9437195
Drug: Alpha-tocopherol and
Normalized name: Alpha-tocopherol and selenium only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol and beta-carotene (50 mg and 20 mg daily respectively)
Study: 3287167
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg per day, five days per week)
Study: 27330807
Drug: CVac maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVac maintenance treatment (10 doses over 56 weeks)
Study: 18300236
Drug: Sorafenib 200
Normalized name: sorafenib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 200 mg orally twice daily and bevacizumab 5 mg/kg to 10 mg/kg intravenously every 2 weeks for 28-day cycles
Study: 12796772
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (4 x 10(9) particle units)
Study: 12796772
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (4 x 10(10) particle units)
Study: 8866624
Drug: Mepyramine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepyramine (0.5 mg.kg‐1) pretreatment
Study: 1346499
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide or dapsone therapy (as second-line treatment)
Study: 6376164
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg curantyl
Study: 6376164
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg no-spa
Study: 31109200
Drug: Methylphenidate (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (36 or 54 mg/day of extended-release)
Study: 28739058
Drug: Acupressure bead
Normalized name: Bead Tree Leaf
DrugBank: Azadirachta indica leaf (DB14352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure bead patch (N=57)
Study: 28739058
Drug: Sham acupressure
Normalized name: ACUPRESSURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupressure patch (N=53)
Study: 25643863
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg Engerix-B
Study: 25643863
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg Engerix-B
Study: 24094079
Drug: Double-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose statin
Study: 9786811
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy alone
Study: 9786811
Drug: Radioiodine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine plus prednisone (3-month course, initial dosage 0.4 to 0.5 mg/kg/day)
Study: 9786811
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral prednisone (80 to 100 mg/d for 6 months) and orbital radiation therapy (20 Gy per eye over 2 weeks)
Study: 3146774
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg o.d. in the morning)
Study: 14738167
Drug: Tablet form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet form of misoprostol (400 microg)
Study: 14738167
Drug: Capsule form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule form of misoprostol (400 microg)
Study: 9339095
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of dinoprostone
Study: 7692109
Drug: Single-dose ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ceftriaxone (2 gm.)
Study: 7692109
Drug: Trimethoprim-sulfamethoxazole (160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (160/800 mg.)
Study: 23214304
Drug: Carepolis gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carepolis gel with propolis content (CT)
Study: 23214304
Drug: Dental Polis
Normalized name: dental polish-varnishes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental Polis DX toothpaste without propolis content (G)
Study: 23214304
Drug: Carepolis gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carepolis gel without propolis content (CG)
Study: 20015704
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin cream (0.075%) applied to the C(5) dermatome
Study: 20015704
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo cream applied to the C(5) dermatome
Study: 15938534
Drug: Fosinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (10 mg daily, increased to 20 mg)
Study: 15938534
Drug: Metoprolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (25 mg twice a day, increased to 75 mg)
Study: 7500456
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C and BCG (alternating therapy)
Study: 2310248
Drug: Verapamil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.1 mg/kg up to 10 mg) intravenously three to five minutes before aortic cross‐clamping
Study: 382148
Drug: 10 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, 20 mg, or 50 mg of domperidone orally
Study: 382148
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg domperidone intravenously
Study: 30641712
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (50000 IU) supplement weekly
Study: 19149522
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once-daily
Study: 19149522
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg twice-daily
Study: 22305833
Drug: High-concentration oxygen
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration oxygen therapy
Study: 30420324
Drug: Low-dose voclosporin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose voclosporin (23.7 mg, twice daily)
Study: 30420324
Drug: High-dose voclosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose voclosporin (39.5 mg, twice daily)
Study: 19164322
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg daily) for 6 months
Study: 17882570
Drug: Additional cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional cycle of oral steroids
Study: 17882570
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no further treatment
Study: 14630595
Drug: Lingzhi (1.1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingzhi (1.1g single dose)
Study: 14630595
Drug: Lingzhi (3.3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingzhi (3.3g acute dose)
Study: 14630595
Drug: Lingzhi (0.72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingzhi (0.72 g/d for 10 days)
Study: 12588694
Drug: Combination Low-Fat/High-FV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Low-Fat/High-FV diet
Study: 9686497
Drug: Plasma adrenomedullin
Normalized name: Adrenomedullin
DrugBank: Adrenomedullin (DB19102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma adrenomedullin levels after treatment
Study: 28741652
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine without morphine and postoperative rectus sheath bupivacaine
Study: 28741652
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine with morphine and postoperative rectus sheath saline
Study: 26109470
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (HbA1c <7.0%, blood pressure ≤135/85 mmHg, total cholesterol ≤3.5 mmol/L)
Study: 23018531
Drug: Avagacestat 15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat 15, 50, 100 or 150 mg once daily for 28 days (young men)
Study: 23018531
Drug: Avagacestat 50
Normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat 50 mg and then 100 mg once daily for 14 days (elderly subjects)
Study: 23018531
Drug: Avagacestat >50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avagacestat >50 mg/day
Study: 8480264
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac in combination with patient controlled intravenous narcotic analgesia (PCA-M)
Study: 8480264
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled intravenous narcotic analgesia (PCA-M) alone
Study: 3099651
Drug: PSK oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSK oral application plus Tegafur
Study: 3099651
Drug: Tegafur oral
Normalized name: tegafur Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur oral administration only
Study: 3099651
Drug: BRM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRM therapy (OK‐432 and PSK)
Study: 26982618
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of H. sabdariffa calyx powder
Study: 22394534
Drug: Daily TERT
Normalized name: TERT-572
DrugBank: TERT-572 (DB17286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TERT of 6‐12 hr
Study: 22394534
Drug: Daily TERT
Normalized name: TERT-572
DrugBank: TERT-572 (DB17286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily TERT of 12‐16 hr
Study: 1683192
Drug: Hydroxyzine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine, 50 mg qhs
Study: 2574555
Drug: Terfenadine, 60
Normalized name: Terfenadine, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 60 mg bid
Study: 6119776
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg day-1 for 8 consecutive weeks
Study: 31562043
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (six cycles of intravenous vinorelbine 25 mg/m2 on days 1, 8, and 15, and daily oral cyclophosphamide 25 mg/m2 on days 1-28)
Study: 31562043
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance chemotherapy (control group)
Study: 30278489
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1 μg/kg (D1)
Study: 30278489
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2 μg/kg (D2)
Study: 17441846
Drug: Patch test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch test with 15 microg Ni/cm(2) on large area
Study: 17441846
Drug: Patch test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch test at higher concentrations of nickel
Study: 11692906
Drug: Iloprost (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (intravenous infusion)
Study: 11692906
Drug: Nifedipine (oral)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (oral)
Study: 3266379
Drug: ketorolac placebo/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac placebo/heparin placebo
Study: 3266379
Drug: ketorolac active/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac active/heparin placebo
Study: 3266379
Drug: ketorolac active/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac active/heparin active
Study: 3266379
Drug: ketorolac placebo/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac placebo/heparin active
Study: 25503557
Drug: 1 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg/kg fentanyl (fent1 group)
Study: 25503557
Drug: 2 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 µg/kg fentanyl (fent2 group)
Study: 17620645
Drug: Household-based water
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Household-based water treatment interventions
Study: 12015391
Drug: t-PA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: t-PA (100 mg intravenously over 15 minutes)
Study: 31623051
Drug: LOP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOP chemotherapy (asparaginase + vincristine + dexamethasone) combined with IMRT
Study: 31623051
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy (cyclophosphamide + pirarubicin + vincristine + dexamethasone) combined with IMRT
Study: 31623051
Drug: LOP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOP chemotherapy combined with IMRT
Study: 31623051
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy combined with IMRT
Study: 27814309
Drug: Osteopathic Manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manipulative Medicine (OMM) bi-weekly for 6 weeks
Study: 27814309
Drug: Weekly counseling
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly counseling sessions (placebo-control) for 6 weeks
Study: 22021102
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (PTA plus SEP)
Study: 18635705
Drug: Rivastigmine (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (4.5 mg po bid) and domperidone (10 mg po qd)
Study: 15044205
Drug: IFN‐gamma 1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐gamma 1b (200 microg) thrice weekly for 6 months
Study: 15044205
Drug: IFN‐gamma 1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐gamma 1b treatment
Study: 9862943
Drug: Admission to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission to the chest-pain observation unit (CPU) with a strict protocol including aspirin, heparin, continuous ST-segment monitoring, determination of creatine kinase isoenzyme levels, six hours of observation.
Study: 8092082
Drug: diet relatively
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: diet relatively high in fat + 30 mg dexfenfluramine (dF)
Study: 30200973
Drug: Sequential POCUS-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential POCUS-assisted protocol
Study: 22297080
Drug: Intraoperative antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative antimicrobial prophylaxis alone (cefazolin 1 g before the surgical incision and every 3 h as intraoperative supplements)
Study: 22297080
Drug: Extended antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antimicrobial prophylaxis (intraoperative administration plus cefazolin 1 g once after closure and twice daily for 2 postoperative days)
Study: 20501957
Drug: EPO (12,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO (12,000 IU intravenous administration)
Study: 20501957
Drug: EPO (12,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO (12,000 IU intravenous administration) in LAD subgroup
Study: 20501957
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline administration)
Study: 9339268
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg t.i.d. xanomeline